Search

Displaying results 2061 - 2070 of 5897 in total
  1. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or wi...

  2. Drug

    Acetyl sulfisoxazole

    go.drugbank.com/drugs/DB14033
    ApprovedVet approved

    It is often combined with erythromycin to treat acute otitis media caused by the bacteria, haemophilus influenzae [L2790].

  3. Drug

    Amyl Nitrite

    go.drugbank.com/drugs/DB01612
    Approved

    Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. … As an inhalant, it also has psychoactive effect which has led to illegal drug use.

  4. Drug

    Valganciclovir

    go.drugbank.com/drugs/DB01610
    ApprovedInvestigational

    After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. … Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections.

  5. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    T-cell engager to receive marketing approval. … Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer.

  6. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.

  7. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    relative to non-engineered anti-CD19 antibodies. … Tafasatimab is designed to bind to and block the activity of the CD19 surface antigen, which ultimately results in the lysis of B-cells (both healthy and malignant).

  8. Drug

    AC-100

    go.drugbank.com/drugs/DB05671
    Investigational

    AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein). It is being developed by Acologix, Inc.

  9. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’

  10. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).